THE USE OF ALENDRONATE GENERICS IN REAL CLINICAL PRACTICE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Surveys of doctors and patients with osteoporosis have shown that generic antiosteoporotic drugs are widely used in real clinical practice. Doctors recommended them more often than other drugs for the treatment of osteoporosis, 49% of all prescription antiresorptive drugs, in addition to the above, 62% of the interviewed patients received generic alendronate preparations during the year preceding the survey. Among those treated with various preparations of alendronate, only 47% of patients were compliant during the year, and notably, the cost of the medication, the duration of treatment, the absence of the drug in the pharmacy, the inconvenience of reception, and poor tolerability influenced the regularity of the use. The appearance of a new form of generic alendronate in the form of effervescent tablets to prepare a buffer solution that has a more favorable safety profile for the gastrointestinal tract can positively influence the adherence of patients to osteoporosis treatment.

Full Text

Restricted Access

About the authors

O. A Nikitinskaya

FSBSI “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova"

N. V Toroptsova

FSBSI “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova"

Email: torop@irramn.ru
MD, Head of the Laboratory of Osteoporosis

References

  1. Торопцова Н.В., Добровольская О.В., Никитинская О.А. и др. Частота антиостеопоротической терапии у пациентов с остеопорозом, осложненным переломами. Остеопороз и остеопатии. 2010;1(прил.):114.
  2. Миронов А.Н. (ред.) Руководство по экспертизе лекарственных средств. М., 2013. Т. 1. 328 с.
  3. Perry G. The European generic pharmaceutical market review: 2006 and beyond. J. Generic Med. 2006;4:4-14.
  4. Toverud E.L., Hartmann K., Hakonsen H.A Systematic Review of Physicians' and Pharmacists' Perspectives on Generic Drug Use: What are the Global Challenges? Appl. Health Econ. Health Policy. 2015;13(Suppl 1):35-45.
  5. Theodorou M., Tsiantou V., Pavlakis A., Maniadakis N., Fragoulakis V., Pavi E., Kyriopoulos J. Factors influencing prescribing behaviour of physicians in Greece and Cyprus: results from a questionnaire based survey. BMC Health Serv. Res. 2009;9:150.
  6. Kennedy J., Teleu I., Mackay K. Unfilled prescriptions of Medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J. Manag. Care Pharm. 2008;14(6):553-60.
  7. Weiss T.W., Henderson S.C., McHorney C.A., Cramer J.A. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr. Med. Res. Opin. 2007;23(9):2193-203.
  8. Yun H., Curtis J.R., Saag K., Kilgore M., Muntner P., Smith W., Matthews R., Wright N., Morrisey M.A., Delzell E. Generic alendronate use among Medicare beneficiaries: are Part D data complete? Pharmacoepidemiol. Drug Saf. 2013; 22(1):55-63.
  9. Kothawala P., Badamgarav E., Ryu S., Miller R.M., Halbert R.J. Systematic review and metaanalysis of real-world adherence to drug therapy for osteoporosis. Mayo Сlin. Proc. 2007;82(12):149-501.
  10. Евстигнеева Л.П., Лесняк О.М., Кузнецова Н.М., Сафонова Ю.А., Булгакова С.В., Кирпикова М.Н., Струнина М.В., Телющенко М.В., Некрасова М.Р., Несмеянова О.Б., Воробьева А.А. Образовательная программа для пациентов с остеопорозом и ее влияние на приверженность к лечению: результаты многоцентрового рандомизированного исследования. Остеопороз и остеопатии. 2012;2:33-7.
  11. Michieli R., Callegaro C. Generic brands in the prevention of fragility fractures. Clin. Cases Miner. Bone Metab. 2015;12(2):109-10.
  12. van Boven J.F., de Boer P.T., Postma M.J., Vegter S. Persistence with osteoporosis medication among newly-treated osteoporotic patients. J. Bone Miner. Metab. 2013;31(5):562-70.
  13. Sheehy O., Kindundu C.M., Barbeau M., LeLorier J. Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos. Int. 2009;20(8):1369-76.
  14. Strom O., Landfeldt E. The association between automatic generic substitution and treatment persistence with oral bisphosphonates. Osteoporos. int. 2012;23(8):2201-209.
  15. Penning-van Beest F.J., Erkens J.A., Olson M., Herings R.M. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr. Med. Res. Opin. 2008;24(5):1337-44.
  16. Tosteson A.N., Do T.P., Wade S.W., Anthony M.S., Downs R.W. Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US. Osteoporos. Int. 2010;21(10):1769-80.
  17. McHorney C.A., Schousboe J.T., Cline R.R., Weiss T.W. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr. Med. Res. Opin. 2007;23:3137-52.
  18. Modi A., Sen S., Adachi J.D., Adami S., Cortet B., Cooper A.L., Geusens P., Mellström D., Weaver J., van den Bergh J.P., Nguyen A.M., Sajjan S.; MUSIC-OS Study Group. Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study. Osteoporos. Int. 2016;27:1227-38.
  19. Kanis J.A., Reginster J.Y., Kaufman J.M., Ringe J.D., Adachi J.D., Hiligsmann M., Rizzoli R., Cooper C. A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos. Int. 2012;23:213-21.
  20. Invernizzi M., Cisari C., Carda S. The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment. Aging Clin. Exp. Res. 2015;27:107-13.
  21. Brown J.P., Davison K.S., Olszynski W.P., Beattie K.A., Adachi J.D. A critical review of brand and generic alendronate for the treatment of osteoporosis. Springer Plus. 2013;2:550.
  22. Drake W., Worsley D., lentle B.C., Kendler D.L. Monitoring oesophageal transit of wax-polished alendronate in healthy postmenopausal women: a new technique for the study of pill transit time. Curr. Ther. Res. 2002;63:103-9.
  23. Epstein S., Geusen P., Fisher J., Hill S., Roy S., Rodan G., et al. Disintegration and esophageal irritation profiles of alendronate formulations: implications for clinical safety and efficacy. J. Appl. Res. 2005;5:253-65.
  24. Hodges L.A., Connolly S.M., Winter J., Schmidt T., Stevens H.N., Hayward M., Wilson C.G. Modulation of gastric pH by a buffered soluble effervescent formulation: a possible means of improving gastric tolerability of alendronate. Int. J. Pharm. 2012;432:57-62.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies